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The ﬁ rst genetic sequencing of Mycobacterium 
tuberculosis was a momentous achievement that 
required years of painstaking eﬀ ort and substantial 
funding.1 It is remarkable that 15 years later, advances 
in laboratory techniques and informatics have enabled 
whole-genome sequencing to be done for hundreds 
of M tuberculosis isolates, making this information 
available for epidemiological studies.2,3 The increasing 
availability of whole-genome sequencing has raised 
questions about the interpretation of this new method,3 
as well as its public health and clinical applications and 
utility. 
In the Lancet Respiratory Medicine, Josephine Bryant 
and colleagues4 report a study comparing molecular 
typing by mycobacterial interspersed repetitive unit-
variable number of tandem repeat (MIRU-VNTR) versus 
whole-genome sequencing for isolates of M tuberculosis 
from 47 consecutive participants in a phase 3 trial of 
tuberculosis treatment. These participants had recurrent 
positive cultures after at least 17 weeks of treatment; 
the two molecular methods were used to determine 
whether these recurrences were a result of relapse or 
re-infection. None of these patients had treatment 
failure, none acquired drug resistance, and 11 were 
HIV-positive. Five recurrences were single isolated 
positive cultures followed by repeated negative cultures 
without treatment; four of these were attributed to 
lab contamination. On the basis of whole-genome 
sequencing of the remaining 42 pairs, 33 were judged 
to be relapses, three were considered re-infection, 
four had evidence of mixed infection initially, of which 
one of the two initial strains relapsed, two had single 
strains initially but mixed infection with two strains was 
identiﬁ ed at the time of recurrence implying that both 
relapse and re-infection had occurred.
Several ﬁ ndings of this study are worthy of comment. 
Of the 42 participants with clinically signiﬁ cant disease 
recurrence, at most ﬁ ve (12%) could be considered to 
be a result of re-infection (including two with mixed 
infection at the time of recurrence), whereas relapse 
accounted for 37 recurrences (including the four 
patients with evidence of mixed infection initially). This 
proportion of re-infections is substantially lower than 
reports from other studies from South Africa, in which 
more than half of those with recurrent tuberculosis had 
evidence of re-infection.5,6 However, in those studies, 
most patients were HIV positive with advanced immune 
suppression, whereas in the Bryant study only 22% had 
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HIV and patients with advanced immune suppression 
were excluded from the parent trial.3 For patients 
with HIV—as long as it is well controlled—the primary 
determinant of long-term outcomes seems to be the 
adequacy of their tuberculosis treatment.
Although whole-genome sequencing is the new test 
being compared with MIRU-VNTR, it is still generally 
assumed to be the new gold standard, in view of the 
wealth of detailed data provided by analysis of single 
nucleotide polymorphisms (SNPs). MIRU-VNTR and 
whole-genome sequencing were concordant in the three 
patients judged to have re-infection, and of the 33 paired 
isolates that had few or no SNP diﬀ erences by whole-
genome sequencing, 27 also had identical MIRU-VNTR 
at all 24 loci. As with many clinical and epidemiological 
comparisons, the discordant cases are the most 
informative. Of the six discordant results deemed relapses 
on the basis of whole-genome sequencing, ﬁ ve (83%) 
were discordant by a single MIRU-VNTR locus, meaning 
that if one deﬁ ned relapse as MIRU-VNTR diﬀ erences of 
not more than one locus, then the two tests would have 
been concordant for all but one case (from the published 
data, concordance of the two methods is diﬃ  cult to judge 
for the six patients with evidence of mixed infections). 
Walker and colleagues3 studied concordance of MIRU-
VNTR and whole-genome sequencing in carefully 
characterised patients, and reported that of 14 paired 
isolates with 1–2 locus diﬀ erences by MIRU-VNTR, ten 
(71%) had 12 or fewer SNP diﬀ erences. They decided 
that such a threshold discriminated between same and 
diﬀ erent isolates. In the same study,3 of 75 isolates from 
epidemiologically unlinked cases, 62 diﬀ ered from at 
least one other isolate by fewer than ﬁ ve SNPs; raising 
questions about the speciﬁ city of whole-genome 
sequencing. 
Bryant and colleagues suggest that whole-genome 
sequencing should be used to classify recurrences in 
all randomised tuberculosis treatment trials, because 
this is the most important and frequent bacteriological 
outcome. Re-infection after treatment is completed 
cannot be aﬀ ected by the regimens evaluated in the 
trial, so will introduce random misclassiﬁ cation and 
reduce the power of the trial by biasing the study 
towards the null. This problem is overcome by molecular 
methods that can accurately distinguish relapse from 
re-infection. In this article, whole-genome sequencing 
was better than MIRU, but if a locus diﬀ erence with 
MIRU-VNTR of zero or one was judged to indicate 
relapse, then the diﬀ erence would have been trivial. 
The earlier methodological study of Walker raised 
important questions about speciﬁ city of whole-genome 
sequencing. An even more important question is that 
of cost, complexity, and accessibility of whole-genome 
sequencing. At present, the unit costs are still substantial 
and the complexity of this test limits it to a few highly 
specialised centres. By contrast, MIRU is simpler to do 
and less costly, although no studies of head-to-head 
cost comparisons have been published. 
Is whole-genome sequencing ready to have a central 
role in tuberculosis clinical trials? For the moment, 
MIRU might still be more practical and cost-eﬀ ective—
enabling investigators to allocate more funds to the 
conduct of the trial itself. But if the cost and accessibility 
of whole-genome sequencing continue to improve, 
this could change. In view of the rapid evolution of this 
technology in the past decade, this seems possible. 
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The ﬁ rst volume and beyond
Today’s December issue marks the end of the ﬁ rst 
volume of The Lancet Respiratory Medicine and the 
editorial team wanted to take this opportunity to 
thank all those who have made the launch possible. The 
authors, reviewers, and our advisory board who have 
submitted content, helped improve papers through 
their critical appraisals, and who have provided a varied 
mix of high quality content that we hope our readers 
have enjoyed and found useful for their clinical practice 
throughout the year. We look forward to receiving your 
submissions for volume two next year.
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